Lipid Formulated Nucleic Acid Dosing to Reduce Infusion Reactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Infusion-related reactions (IRRs) and hypersensitivity reactions associated with lipid-formulated nucleic acid molecules, such as siRNA, are not effectively managed by existing methods, leading to adverse symptoms in subjects during drug administration.
Innovation Solution
Administering a first dose of a lipid-formulated RNA molecule at a reduced amount or rate before the second dose, or over a shorter time period compared to the second dose, to mitigate IRRs and hypersensitivity reactions, using specific dose ratios and time intervals to minimize adverse responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a lipid-formulated nucleic acid molecule is administered at a high dose rate, then the therapeutic effect is improved, but infusion-related reactions and hypersensitivity reactions increase
Solution Approach 1:
A pre-dose or first dose is administered before the full therapeutic dose to prepare the subject's system and reduce subsequent hypersensitivity reactions. This preliminary action allows the immune system to adapt to the lipid formulation without triggering severe IRRs, enabling subsequent administration of higher therapeutic doses.
Solution Approach 2:
The total dose is divided into multiple administration periods including a pre-dose phase followed by the main therapeutic dose. This periodic administration strategy allows the system to tolerate the formulation better over time while still achieving the required therapeutic exposure.
2Object-affected harmful factors
If the infusion time is extended to reduce IRRs, then hypersensitivity reactions are reduced, but treatment time increases
Solution Approach 1:
By administering a pre-dose first, the subject's system is prepared in advance, which reduces the need for prolonged infusion times during subsequent therapeutic dosing. The preliminary exposure desensitizes the system, allowing faster administration of the main therapeutic dose.
Solution Approach 2:
The total treatment time is segmented into a pre-dose phase and a main therapeutic phase. The pre-dose phase uses extended infusion to minimize reactions, while the main therapeutic phase can be administered more quickly since the system is already adapted, thus reducing the overall time penalty.
3Object-affected harmful factors
If a pre-dose is administered to reduce IRRs, then hypersensitivity reactions are reduced, but the total number of administration steps increases
Solution Approach 1:
The pre-dose and main therapeutic dose are merged into a single treatment protocol with standardized intervals. This integration reduces the perceived complexity by providing a clear, multi-step regimen that is easier to manage than ad-hoc dose adjustments.
Solution Approach 2:
The dosing regimen follows a periodic pattern with defined intervals between pre-dose and main dose administrations. This regularity simplifies scheduling and monitoring, making the increased number of steps more manageable through predictable timing.
Data Source
AI summary
Methods, kits and devices for dosing a subject to reduce a hypersensitivy response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed.